Compass Therapeutics

Ginkgo Bioworks (NYSE: DNA) Stock Quote Follow

Last Trade: US$1.25 -0.02 -1.57
Volume: 4,368,277
5-Day Change: -2.34%
YTD Change: -26.04%
Market Cap: US$1.840B

Latest News From Ginkgo Bioworks

March 2, 2023
Ginkgo Bioworks Announces Participation in Cowen's 43rd Annual Health Care Conference
BOSTON , March 2, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in Cowen's 43 rd Annual Health Care Conference, including: Fireside chat on Monday, March 6, 2023 , at 9:10 a.m. ET SynBio & AI Driven Drug Discovery panel on Monday, March 6, 2023 , at 4:40 p.m. ET... Read More
March 1, 2023
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
$478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we drive towards profitability BOSTON , March 1, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA,... Read More
February 28, 2023
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results
Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash... Read More
January 18, 2023
NAMUH and Ginkgo Bioworks Announce Partnership to Produce Multiple Infant Nutrition Products
Ginkgo will develop and optimize strains to produce functional oligosaccharides for NAMUH's infant nutrition products BOSTON , Jan. 18, 2023 /PRNewswire/ -- NAMUH, an infant nutrition company, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those... Read More
January 17, 2023
Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health Announce Collaboration to Implement Biosecurity Capabilities in Ukraine
The collaboration will launch a pilot program for wastewater-based pathogen monitoring to support critical public health needs BOSTON and KYIV, Ukraine , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Public Health Center of the Ukraine Ministry of Health today announced a new collaboration to conduct a wastewater testing pilot... Read More
January 17, 2023
Ginkgo Bioworks and XpresCheck Expand CDC's Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airports BOSTON and NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program to... Read More
January 11, 2023
Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and puts Ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment Strong growth among biopharma customers as Ginkgo has scaled its mammalian cell engineering capabilities, including recently opening Bioworks7,... Read More
January 9, 2023
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON and BOSTON , Jan. 9, 2023 /PRNewswire/ -- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics. Most gene therapies today leverage viral delivery systems. While... Read More
January 6, 2023
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications BOSTON , Jan. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its... Read More
January 5, 2023
Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
Initial focus of partnership will aim to develop cancer therapeutics PLYMOUTH, Mich. and BOSTON , Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. Initially, Ginkgo and... Read More
January 4, 2023
Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m. PT ( 2:15 p.m. ET ). He plans to discuss Ginkgo's biopharma capabilities and end-to-end services offerings,... Read More
December 20, 2022
Ginkgo Bioworks and Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana
Collaboration aims to leverage innovative biosecurity capabilities to promote public health, global health security, and the development of the bioeconomy BOSTON and GABORONE, Botswana , Dec. 20, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH"), representing the Government of the Republic of Botswana , today... Read More
HealthStocksHub
December 8, 2022
Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond
Enzyme Intelligence Virtual Event on December 15, 2022 gives overview of Ginkgo's approach to machine learning-guided enzyme engineering BOSTON , Dec. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme... Read More
December 2, 2022
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
BOSTON , Dec. 2, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that in connection with its transaction with Bayer CropScience LP ("Bayer") on October 17, 2022 , Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. ("Zymergen") on... Read More
November 14, 2022
Ginkgo Bioworks Reports Third Quarter 2022 Financial Results
15 new Cell Programs added and $66 million of Total revenue in Q3 2022 Closed four acquisitions in October, including Zymergen and Bayer's West Sacramento agricultural biologicals capabilities, enabling commencement of integration and pursuit of new growth opportunities End of quarter cash balance of over $1.3 billion provides continued financial flexibility BOSTON , Nov. 14, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings,... Read More
October 25, 2022
Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia Announce Plans to Develop Biosecurity and Biotechnology Capabilities for Global Public Health
Collaboration aims to bolster capabilities of key public health and research institutions, launch new biosecurity initiatives, and drive the development of the bioeconomy Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Ministry of Investment of Saudi Arabia ("MISA"), representing the Kingdom of Saudi Arabia , today announced that they have entered into a non-binding Memorandum of... Read More
October 20, 2022
Bolt Threads Announces Latest Collaboration with Ginkgo Bioworks to Optimize its Mylo™ Material
Program builds on the existing relationship between the partners following existing b-silk™ protein optimization project Bolt Threads , a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio... Read More
October 19, 2022
Ginkgo Bioworks Completes Acquisition of Zymergen
Today, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and Zymergen (Nasdaq: ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks... Read More
October 17, 2022
IARPA, Ginkgo Bioworks and Draper Announce New Technologies to Detect Engineered DNA
The Intelligence Advanced Research Projects Activity (IARPA), the research and development arm of the U.S. Intelligence community, Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming and Draper, a nonprofit engineering innovation firm, today announced the completion of IARPA's Finding Engineering-Linked Indicators ( FELIX) program . The program was created to augment and improve current... Read More
October 11, 2022
Ginkgo Bioworks Announces Collaboration with Merck to Improve Active Pharmaceutical Ingredient Manufacturing
Ginkgo to engineer key biocatalytic enzymes for potential use in Merck's drug manufacturing processes Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Merck, known as MSD outside the United States and Canada , to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. Through this... Read More
October 4, 2022
Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Circularis, a biotechnology company with a proprietary circular RNA and promoter screening platform. When circularized, RNA is much longer-lived in cells, improving its robustness as a potential therapeutic modality. The Circularis platform also allows ultra-high-throughput screening of promoters and... Read More
October 4, 2022
Ginkgo Bioworks Acquires Adaptive Laboratory Evolution Company Altar
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the tuck-in acquisition of Altar, a French biotechnology company that has developed a proprietary adaptive evolution platform. A fleet of Altar's automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo's Foundry to serve customers across food and beverage, biofuels, biomaterials, cosmetics,... Read More
September 12, 2022
Ginkgo Bioworks Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health
The White House today announced that President Biden intends to appoint Renee Wegrzyn , PhD, as the first Director of the Advanced Research Projects Agency for Health (ARPA-H). Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming. ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot... Read More
September 1, 2022
Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi , Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools. In this new role, Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities. Dr. Mahdavi brings more than 20 years... Read More
August 19, 2022
Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets
Transaction is expected to bolster Ginkgo's growing biosecurity platform and provide expanded epidemic tracking, modeling, and forecasting offerings to public health leaders and communities Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware -based public benefit corporation. Under... Read More
August 15, 2022
Ginkgo Bioworks Reports Second Quarter 2022 Financial Results
$145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new Cell Programs added in Q2 2022, representing 86% growth over Q2 2021 Pending acquisitions of Zymergen and Bayer's West Sacramento agricultural biologicals capabilities expected to enable new growth opportunities in the coming years Approximately $1.4 billion cash balance provides continued multi-year runway as Ginkgo drives towards... Read More
August 15, 2022
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expected to support public health and biosecurity services totaling approximately $16 million, with an overall potential to exceed $61... Read More
August 15, 2022
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC's Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention's (CDC's) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022 . The... Read More
August 11, 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the... Read More
August 11, 2022
Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda
Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda , today announced that they have entered into a Memorandum of Understanding ("MOU") with... Read More
August 8, 2022
Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation
Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022 Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022 , on Monday, August 15, 2022 , beginning at 4:30 p.m. ET . The presentation details and webcast link will be available... Read More
August 4, 2022
Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan , PhD, CPA has joined its Board of Directors, effective August 2, 2022 . Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives. "As a pioneer in... Read More
July 25, 2022
Ginkgo to Acquire Zymergen
Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end markets Zymergen's... Read More
July 25, 2022
Ginkgo Bioworks and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities
Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in... Read More
HealthStocksHub
July 18, 2022
Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broader collaboration with Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies. Through this partnership, Sumitomo Chemical will leverage... Read More
July 14, 2022
Ginkgo Bioworks Publishes Inaugural Sustainability Report
The report, "Caring at Ginkgo," outlines the company's approach to sustainability, internal governance structures, and how its cell engineering platform is deployed Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report . The report highlights the company's vision for and approach to sustainability, includes case studies across its ecosystem, and... Read More
June 10, 2022
Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43 rd Annual Global Healthcare Conference, on June 15, 2022 , at 10:40 a.m. PT . Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events... Read More
June 7, 2022
Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk , a leading global healthcare company, to create novel expression hosts for pharmaceutical products. Today, hundreds of millions of people are living with diabetes, obesity, and other serious chronic diseases, putting a strain on individuals, families, and healthcare systems. More effective... Read More
June 6, 2022
Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform
Through real-time metabolite monitoring, Bitome's technology is expected to support accelerated product development timelines across Ginkgo's portfolio of cell programs Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from Bitome, a company pioneering real-time metabolite monitoring for faster biological product development. Bitome has... Read More
June 2, 2022
Ginkgo Bioworks Announces Participation in William Blair's 42nd Annual Growth Stock Conference
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42 nd Annual Growth Stock Conference, on June 9, 2022 , at 11:20 a.m. CT . Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.... Read More
May 18, 2022
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
Partnership recognizes the importance of global cooperation to prevent and respond to pandemics By leveraging Ginkgo's large-scale biosecurity platform and Qatar's pioneering investments in biotechnology, collaboration aims to build new biosecurity capabilities and accelerate the establishment of a global pathogen monitoring network Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First... Read More
May 16, 2022
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021 11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021 Increasing full year guidance for Total revenue from $325 – $340 million to $375 – $390 million , reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance Recently announced plans to expand platform capabilities in agricultural biologicals... Read More
HealthStocksHub
May 11, 2022
Evo Foods and Ginkgo Bioworks Announce Partnership to Develop Animal-Free Egg Products
Evo Foods will leverage Ginkgo's cell engineering capabilities to explore recombinant production methods for egg proteins Evo Foods , a consumer packaged goods company creating the next generation of plant-based substitutes for animal products, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell... Read More
HealthStocksHub
May 9, 2022
Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation
Presentation and Q&A session scheduled for post-market on Monday, May 16, 2022 Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2022 , on Monday, May 16,... Read More
April 22, 2022
Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer
Planned transaction expands Ginkgo's horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to customers of all sizes in the agriculture industry Under the proposed transaction, Ginkgo to acquire Bayer's West Sacramento agricultural biologicals site and team, adding a 175,000-square-foot R&D facility with pilot scale... Read More
HealthStocksHub
April 14, 2022
Light Bio Partners with Ginkgo Bioworks to Optimize the Brightness of Glowing Plants through Bioluminescence Engineering
Leveraging Ginkgo's plant-cell assay and engineering capabilities to aid Light Bio in optimizing the performance of its light-emitting plants Light Bio, Inc. , a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB